Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 14/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826872 | 1.00 | TNF (0.40) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1826871 | 0.86 | TNF (0.41) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1826997 | 0.85 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL3523754 | 0.82 | TNF (0.43) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3531499 | 0.82 | TNF (0.43) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3523757 | 0.81 | UTS2R (0.47) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8313746 | 0.81 | TNF (0.42) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1826156 | 0.81 | TNF (0.48) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1826154 | 0.81 | TNF (0.48) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27942400 | 0.78 | TNF (0.45) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1606256-B1 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | CELGENE CORPORATION | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | PDE4A, PDE12, PDE4B | TNF 2494/4885PDE4A 1/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.